Back
TScan Therapeutics, Inc. 10K Form
Sell
38
TCRX
TScan Therapeutics, Inc.
Last Price:
$1.07
Seasonality Move:
1.49%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive TCRX News And Ratings
See the #1 stock for the next 7 days that we like better than TCRX
TCRX Financial Statistics
Sales & Book Value
| Annual Sales: | $2.8M |
|---|---|
| Cash Flow: | $-33.9M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $2.54 |
| Price / Book: | 0.42 |
Profitability
| EPS (TTM): | -1.11950 |
|---|---|
| Net Income (TTM): | $-142.6M |
| Gross Margin: | $-1.3M |
| Return on Equity: | -71.23% |
| Return on Assets: | -44.21% |
TScan Therapeutics, Inc. Earnings Forecast
Key TScan Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 6 years for TCRX is -45.88%.
-
The Selling, General & Administrative Expenses for TCRX have been equal to 1,075.53% of Gross Profit Margin.
-
The Research & Development expenses have been 3,692.12% of Revenue.
-
The Net Earning history of TCRX is -4,527.66% of Total Revenues.
-
Per Share Earnings over the last 6 years have been positive in 3 years.
TScan Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | TCRX |
| Website: | tscan.com |
Debt
| Debt-to-Equity Ratio: | 0.66 |
|---|---|
| Current Ratio: | 6.44 |
| Quick Ratio: | 6.32 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
TCRX Technical Analysis vs Fundamental Analysis
Sell
38
TScan Therapeutics, Inc. (TCRX)
is a Sell
Is TScan Therapeutics, Inc. a Buy or a Sell?
-
TScan Therapeutics, Inc. stock is rated a SellThe current TScan Therapeutics, Inc. [TCRX] share price is $1.06. The Score for TCRX is 38, which is 24% below its historic median score of 50, and infers higher risk than normal.